Is Tirzepatide Legal in Australia?
A neutral guide to tirzepatide's regulatory status in Australia, its Schedule 4 classification, the ARTG, the TGA's role and research-use-only material.
The short answer
Tirzepatide is a prescription-only medicine in Australia. It is classified as a Schedule 4 substance under the Poisons Standard, which means it is lawfully supplied for human use only on the authority of a prescription issued by an appropriately registered health practitioner. It is not a substance that can be sold over the counter or marketed directly to the public for personal use.
Tirzepatide is also entered on the Australian Register of Therapeutic Goods (ARTG) under the brand name Mounjaro, which is registered by Eli Lilly Australia. A medicine being on the ARTG means the Therapeutic Goods Administration (TGA) has assessed that specific registered product for quality, safety and efficacy as a therapeutic good.
Separately from the registered medicine, tirzepatide also exists as a laboratory reference compound sold strictly for research use only. Research-use-only material is not a medicine, is not approved for human or animal use, and is intended solely for in-vitro laboratory investigation by qualified researchers. The sections below explain how these different categories sit within Australian law.
What tirzepatide is
Tirzepatide is a synthetic peptide described in the scientific literature as a dual agonist. It is designed to engage two receptors, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Published pharmacology research characterises it as an imbalanced dual incretin receptor agonist, with studies noting a greater degree of engagement at the GIP receptor relative to the GLP-1 receptor.
Because it is a defined molecular entity, tirzepatide can appear in two very different contexts. One is as the active ingredient inside a TGA-registered prescription medicine. The other is as a research chemical supplied to laboratories as a reference standard. These are distinct legal categories even though the underlying molecule shares a name.
How the TGA and the Poisons Standard classify it
The TGA is the Australian Government regulator responsible for therapeutic goods, including prescription medicines. One of its functions is administering the scheduling of substances through the Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).
Under the Poisons Standard, tirzepatide sits in Schedule 4, the category for Prescription Only Medicines. Schedule 4 substances are those that the regulator has determined should be available for human use only through a prescription, so that use occurs under professional oversight. This classification is a legal control on how the substance may be supplied for therapeutic purposes in Australia.
- Schedule 4 means Prescription Only Medicine under the Poisons Standard
- The TGA administers scheduling decisions through the SUSMP
- Prescription-only status applies to supply for human therapeutic use
- Scheduling is a legal control, separate from any individual product's ARTG entry
The ARTG and the Mounjaro registration
The Australian Register of Therapeutic Goods is the official database of therapeutic goods that may be lawfully supplied in Australia. When a medicine is entered on the ARTG, it means a specific, defined product has been assessed by the TGA and carries an ARTG number.
Tirzepatide is on the ARTG as the registered medicine Mounjaro, sponsored by Eli Lilly Australia, with entries covering various pre-filled pen and vial presentations. It is important to understand that an ARTG registration applies to that particular registered product, manufactured and labelled under the sponsor's approval. It does not extend approval to unregistered material that happens to contain the same molecule.
For readers comparing categories, our guide to buying research peptides in Australia explains how registered medicines differ from non-approved laboratory material in more general terms.
What research-use-only means in law
Research-use-only (RUO) is a labelling and supply category used for substances intended solely for laboratory investigation. RUO material is not a medicine. It is not registered on the ARTG, it is not assessed by the TGA for human or animal use, and it must not be presented, supplied or used as a therapeutic good.
Because tirzepatide is a scheduled substance, any material bearing its name is treated seriously under Australian law regardless of how it is described. A research-chemical label does not create a pathway for personal human use, nor does it override the Schedule 4 controls that apply to therapeutic supply. RUO compounds are intended for qualified researchers conducting in-vitro work, and they should be documented, labelled and handled accordingly.
This distinction matters because the legality of a substance in Australia depends not only on its chemical identity but also on the purpose for which it is supplied and used, and on whether the specific product is approved for that purpose.
WADA and anti-doping status
The World Anti-Doping Agency (WADA) maintains a Prohibited List and a separate Monitoring Program. According to publicly reported information, tirzepatide and related compounds have featured on the WADA Monitoring Program, which means WADA is observing patterns of use rather than prohibiting the substance outright.
Monitoring Program status can change over time following WADA's own review processes. Athletes and anyone bound by anti-doping rules should always confirm the current status directly with WADA and their national anti-doping organisation, because this is an area that is reviewed and may be updated. This article does not provide anti-doping advice.
How tirzepatide compares to related compounds
Tirzepatide is often discussed alongside other incretin-related research peptides. Each compound has its own distinct regulatory position, and it is a mistake to assume that the status of one applies to another.
For context on closely related compounds, our regulatory explainer on retatrutide covers another investigational multi-receptor agonist, and our overview of BPC-157 addresses a different class of research peptide entirely. These comparisons are for regulatory education only and do not imply any equivalence in approval status.
Is retatrutide legal in Australia? Is BPC-157 legal in Australia?
Why the category matters when evaluating a supplier
Because tirzepatide spans a registered prescription medicine and a research-use-only category, clear and accurate labelling is essential. A trustworthy supplier of research material presents compounds honestly as laboratory reference items, does not make therapeutic claims, and does not position non-approved material as a medicine.
If you are assessing where research material comes from, our guide on how to spot a trustworthy supplier outlines the signals worth checking, including transparent labelling and documentation. Accurate categorisation protects both researchers and the integrity of Australia's regulatory framework.
Key takeaways
To summarise the regulatory picture in neutral terms:
- Tirzepatide is a Schedule 4 Prescription Only Medicine under the Poisons Standard
- It is on the ARTG as the registered medicine Mounjaro, sponsored by Eli Lilly Australia
- An ARTG registration applies to that specific registered product, not to unapproved material
- Research-use-only tirzepatide is not a medicine and is not approved for human or animal use
- WADA has listed tirzepatide on its Monitoring Program, a status that can change and should be verified
- Legality depends on the substance, the purpose of supply and whether the product is approved for that purpose
Frequently asked questions
Is tirzepatide legal in Australia?
Tirzepatide is a Schedule 4 prescription-only medicine in Australia and is on the ARTG as Mounjaro. For human therapeutic use it is lawful only on prescription. Research-use-only material is a separate, non-medicine category that is not approved for human or animal use.
Is tirzepatide prescription-only in Australia?
Yes. Under the Poisons Standard, tirzepatide is classified as Schedule 4, which is the Prescription Only Medicine category. Lawful therapeutic supply for human use requires a prescription from an appropriately registered health practitioner.
Is tirzepatide on the ARTG?
Yes. Tirzepatide is entered on the Australian Register of Therapeutic Goods as the registered medicine Mounjaro, sponsored by Eli Lilly Australia, across several presentations. The registration applies to that specific approved product.
What does research-use-only mean for tirzepatide?
Research-use-only tirzepatide is supplied as a laboratory reference compound for in-vitro investigation by qualified researchers. It is not a medicine, is not on the ARTG, is not assessed by the TGA for human or animal use, and must not be used therapeutically.
What is tirzepatide classified as under the Poisons Standard?
Tirzepatide is listed in Schedule 4 of the Poisons Standard, the category for Prescription Only Medicines. The TGA administers scheduling through the Standard for the Uniform Scheduling of Medicines and Poisons.
Is tirzepatide banned by WADA?
Publicly reported information indicates tirzepatide has featured on the WADA Monitoring Program rather than the Prohibited List, meaning WADA is observing its use. This status can change, so anyone bound by anti-doping rules should confirm the current position with WADA and their national anti-doping body.
What is the TGA's role with tirzepatide?
The TGA is the Australian regulator for therapeutic goods. It assesses and registers medicines on the ARTG and administers the scheduling of substances through the Poisons Standard. It classified tirzepatide as a Schedule 4 prescription medicine and registered the Mounjaro product.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.